Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Dr Michael Mosley's son is picking up his dad's weight loss campaign with the publication of a new book. Michael Mosley was a ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...

Dr Jack Mosley is an expert in weight loss drugs but says there are important things people need to know when taking them ...